Nazzal Zaher A, Khazneh Emad N, Rabi Razan A, Hammoudeh Ahlam A, Ghanem Ahmed F, Zaidan Mohammed A
Department of Family and Community Medicine, Faculty of Medicine and Health Sciences, An-Najah National University, Nablus, State of Palestine.
Department of Nephrology, An-Najah National University Hospital, Nablus, State of Palestine.
Int J Nephrol. 2020 May 13;2020:2683123. doi: 10.1155/2020/2683123. eCollection 2020.
The kidney affects the thyroid gland causing various derangements in its function whenever the kidney is impaired, even with a minor imperfection in its job, and this makes dialysis patients more prone to thyroid disorders with subsequent increase in mortality and morbidity. This study aims to assess the prevalence of thyroid disease (hypo- and hyperthyroidism) among dialysis patients and their associated factors.
This cross-sectional study was conducted in the dialysis unit of An-Najah National University Hospital. 209 dialysis patients (60% were male, 57.6 ± 14.5 years, mean age) meeting our inclusion criteria were tested for thyrotropin (TSH) and free thyroxine (FT4) in addition to routine laboratory tests. . The prevalence of hypothyroidism was assessed as 16.3% (95% CI = 11.29% to 21.3%), overt hypothyroidism was 9.1%, and subclinical hypothyroidism was 7.2%. Subclinical hyperthyroidism prevalence was 1%, and no overt hyperthyroidism cases were reported. We observed no significant association between thyroid state and age, gender, duration of dialysis, or weight. . Hypothyroidism (both subclinical and overt type) is commonly seen in dialysis patients, and its symptoms are ordinary complains even in euthyroid dialysis patients, and this warrants screening programs and more studies on the efficacy of thyroid hormone supplements.
肾脏会影响甲状腺，每当肾脏功能受损时，即使其功能存在轻微缺陷，也会导致甲状腺功能出现各种紊乱，这使得透析患者更容易患甲状腺疾病，进而增加死亡率和发病率。本研究旨在评估透析患者中甲状腺疾病（甲状腺功能减退和亢进）的患病率及其相关因素。
本横断面研究在纳贾赫国立大学医院透析科进行。除常规实验室检查外，对209名符合纳入标准的透析患者（60%为男性，平均年龄57.6±14.5岁）进行了促甲状腺激素（TSH）和游离甲状腺素（FT4）检测。甲状腺功能减退的患病率评估为16.3%（95%置信区间=11.29%至21.3%），显性甲状腺功能减退为9.1%，亚临床甲状腺功能减退为7.2%。亚临床甲状腺功能亢进患病率为1%，未报告显性甲状腺功能亢进病例。我们观察到甲状腺状态与年龄、性别、透析时间或体重之间无显著关联。甲状腺功能减退（亚临床型和显性型）在透析患者中很常见，即使在甲状腺功能正常的透析患者中，其症状也很常见，这就需要开展筛查项目，并对甲状腺激素补充剂的疗效进行更多研究。
